ATRC
AtriCure, Inc. · Healthcare · Medical - Instruments & Supplies
Momentum inputs (comparable managers):
holder breadth -5.6% ·
share flow -1.8% ·
net new positions -11.8%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 18.02K | $654,370 | n/a | −1 |
| Q2 2026 | 102 | +4 | 36.26M | $1.02B | +10 | −5 |
| Q1 2026 | 100 | +5 | 35.01M | $1.03B | +10 | −6 |
| Q4 2025 | 96 | +1 | 36.16M | $1.43B | +2 | n/a |
| Q3 2025 | 17 | -1 | 19.38M | $683.04M | n/a | −2 |
| Q2 2025 | 16 | -1 | 18.32M | $600.37M | n/a | −1 |
| Q1 2025 | 14 | 0 | 6.98M | $225.02M | +1 | −1 |
| Q4 2024 | 14 | +1 | 5.72M | $174.87M | +2 | −1 |
| Q3 2024 | 12 | -1 | 4.89M | $137.07M | n/a | −1 |
| Q2 2024 | 13 | n/a | 5.61M | $127.65M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 4.84M | -1.3% | $170.64M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | Wellington Management ✦ | 4.29M | +8.1% | $151.30M | 0.0% | ▲ Add | 6 | SEC ↗ ×6 |
| 3 | BlackRock ✦ (passive) | 4.00M | -0.6% | $140.90M | 0.0% | ▼ Trim | 2 | SEC ↗ ×15 |
| 4 | State Street Global Advisors ✦ (passive) | 1.26M | -0.7% | $44.57M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.19M | +0.8% | $41.99M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Goldman Sachs Group ✦ | 777.31K | n/a | $27.40M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Marshall Wace ✦ | 559.17K | -44.4% | $19.71M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 8 | JPMorgan Chase ✦ | 453.97K | n/a | $16.00M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 9 | Two Sigma Investments ✦ | 452.88K | +9.9% | $15.96M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 394.00K | +45.8% | $13.89M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 11 | Millennium Management ✦ | 353.26K | -1.9% | $12.45M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 258.80K | -31.5% | $9.12M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Morgan Stanley ✦ | 188.82K | n/a | $6.66M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 14 | Adage Capital Partners ✦ | 175.00K | -36.4% | $6.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 84.17K | +24.3% | $2.97M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 16 | T. Rowe Price ✦ | 48.46K | +4.6% | $1.71M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 45.50K | -66.2% | $1.60M | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $342,053 | was 0.0% |
| D. E. Shaw & Co. | $254,820 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 221 holders, 49.84M shares, $1.41B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.52K sh · $271,140
Director · 5.31K sh · $288,071
Officer · 3.66K sh · $201,135
Officer · 7.76K sh · $407,558
Officer · 9.37K sh · $458,099
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology